GC Biopharma Maps mRNA-LNP Degradation
GC Biopharma announced on August 7 that it has published research results closely analyzing the physicochemical stability and changes of mRNA-LNP vaccines in the SCIE-indexed international journal ‘Pharmaceutical Research’.The mRNA platform is considered an innovative technology capable of rapid res
On August 7, GC Biopharma released research detailing the stability and changes of mRNA-LNP vaccines, published in the SCIE-indexed journal 'Pharmaceutical Research.' mRNA vaccines, while innovative for rapid pandemic response, are vulnerable to environmental changes due to their formulation. The lack of global quality control standards for mRNA technology poses a challenge for manufacturers seeking verified analysis systems.
To address this, GC Biopharma conducted forced degradation studies simulating conditions like temperature changes, oxidation, hydrolysis, and physical vibration. The company found correlations between mRNA purity and LNP structural changes on protein expression efficacy. Advanced analytical techniques, including ion-pair reversed-phase high-performance liquid chromatography, capillary electrophoresis, Cryo-TEM, ultra-performance liquid chromatography with charged aerosol detection, and liquid chromatography-tandem mass spectrometry, were employed.
GC Biopharma intends to integrate its established analysis platform into various mRNA therapeutics' manufacturing processes, aiming to enhance impurity control, process optimization, and future quality control guidelines. Hong Jeong-woon, GC Biopharma's R&D QM Unit Head, emphasized the study's significance in analyzing quality characteristics and degradation pathways, proposing analytical techniques as a core standard for quality reliability in mRNA-based products.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
